Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.57 |
| ▸ | RARB | P10826 | 6/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | MPL | P40238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175800 | 0.87 | MKNK1 (0.58) | MKNK1MKNK2RARBCYP11B2CYP11B1 | |
| SCHEMBL15750344 | 0.82 | RARB (0.72) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL1758341 | 0.80 | MKNK1 (0.60) | MKNK1MKNK2CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL11609662 | 0.78 | ALDH1A1 (0.60) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL2530451 | 0.78 | GPR84 (0.44) | RARBCYP11B2CYP11B1MEN1ALDH1A1 | |
| SCHEMBL11561799 | 0.78 | RARB (0.57) | MKNK1MKNK2RARBMEN1ALDH1A1 | |
| SCHEMBL12647206 | 0.77 | MKNK1 (0.69) | MKNK1MKNK2CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL2241887 | 0.77 | RARB (0.73) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL607614 | 0.77 | RARB (0.62) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL6754398 | 0.76 | MKNK1 (0.67) | MKNK1MKNK2CYP11B2CYP11B1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885RARB 2397/4885 |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4532/4885MKNK2 4591/4885RARB 2303/4885 |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | MKNK1 4334/4885MKNK2 4509/4885RARB 2026/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885RARB 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.